Short interest for Celldex Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Celldex Therapeutics's stock. Short interest data is updated every two weeks.

Celldex Therapeutics Stock (NASDAQ:CLDX), Short Interest Report

Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

News

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ARVN

ARWR

CLDX

CRNX

DELL

EVBG

MLTX

NTAP

OPRA

PTCT

RDNT

RGNX

RMBS

ROOT

RPAY

SANA

SMCI

XPOF

YMAB

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Penny Stocks

ACON

AEHL

AGTI

AKLI

ATCH

BENF

BFLY

BREA

CTCX

DHAI

DOGZ

FRPT

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IBRX

ITRI

KRYS

LUNR

MARA

MIST

NBSE

NEPT

NUWE

OCGN

PSNY

ROMA

SELX

SGRY

SKYT

TBIO

TEVA

THMO

TRNR

VERO

WRLD

ZJYL

ZVSA

Shares of  Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.

Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Short Ideas

Pre-Market Outlook

ESPR

MGNX

VRCA

As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 4 Health Care Stocks That May Crash This Month

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

In the latest quarter, 4 analysts provided ratings for Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.25, a high estimate of $90.00, and a low estimate of $67.00. This current average has increased by 10.07% from the previous average price target of $72.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715112030_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>-</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Celldex Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celldex Therapeutics analyst ratings.</a>
<h2>Delving into Celldex Therapeutics's Background</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
<h3>Financial Insights: Celldex Therapeutics</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Celldex Therapeutics showcased positive performance, achieving a revenue growth rate of 156.11% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1048.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Celldex Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -12.81%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.61%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Unveiling 4 Analyst Insights On Celldex Therapeutics

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.69) by 18.84 percent. This is a 9.68 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $156.00 thousand which missed the analyst consensus estimate of $920.00 thousand by 83.04 percent. This is a 83.87 percent decrease over sales of $967.00 thousand the same period last year.

Earnings

Earnings Beats

Earnings Misses

Celldex Therapeutics Q1 EPS $(0.56) Beats $(0.69) Estimate, Sales $156.00K Miss $920.00K Estimate

Biotech

General

Celldex Completes Enrollment In Phase 2 Study Of Barzolvolimab In Patients With Chronic Inducible Urticaria

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Overweight and maintains $67 price target.

Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target

MDGL: 28% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37743641">Madrigal Pharmaceuticals shares are trading higher after the company announced FDA approval of Rezdiffra for the treatment of patients with noncirrhotic NASH with moderate to advanced liver fibrosis.</a>
CLDX: 53% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37740702">Cardlytics shares are trading higher after the company reported better-than-expected Q4 revenue results and issued Q1 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $12 to $15.</a>
ADBE: -12% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37740107">Adobe shares are trading lower after the company reported Q1 financial results and issued weak guidance. Also, multiple firms lowered their respective price targets on the stock.</a>

ADBE

MDGL

Market-Moving News for March 15th

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Shares of The Cooper Companies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/coo#NYSE">COO</a>) rose sharply during Friday&rsquo;s session after the company reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/COO/earnings">financial results and raised guidance</a>.
Cooper Companies posted adjusted earnings of 85 cents per share, beating market estimates of 78 cents per share. The company&rsquo;s quarterly sales came in at $931.60 million versus expectations of $915.94 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The Cooper Companies shares rose 7.4% to $100.61 on Friday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Dell Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) jumped 26.3% to $119.52 as the company reported better-than-expected fourth-quarter financial results and increased its annual cash dividend by 20%.</li>
<li>Sweetgreen, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sg#NYSE">SG</a>) rose 26% to $16.05 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Everbridge, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evbg#NASDAQ">EVBG</a>) climbed 24.5% to $35.19 after it amended and restated the previously announced merger agreement with Thoma Bravo.</li>
<li>NetApp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntap#NASDAQ">NTAP</a>) shares rose 24.4% to $110.85 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>Xponential Fitness, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpof#NYSE">XPOF</a>) surged 24% to $12.50 following strong quarterly sales.</li>
<li>Opera Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opra#NASDAQ">OPRA</a>) rose 18.8% to $14.47 following strong sales.</li>
<li>REGENXBIO Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgnx#NASDAQ">RGNX</a>) rose 18.5% to $20.66.</li>
<li>RadNet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>) gained 18.1% to $44.71 following strong quarterly results.</li>
<li>Sana Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sana#NASDAQ">SANA</a>) gained 17.3% to $11.78 after the company reported a year-over-year increase in fourth-quarter financial results.</li>
<li>Tidewater Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdw#NYSE">TDW</a>) rose 15.3% to $80.73 following fourth-quarter financial results.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ymab#NASDAQ">YMAB</a>) climbed 14.3% to $19.09 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Repay Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rpay#NASDAQ">RPAY</a>) gained 14.4% to $9.94 following upbeat quarterly results.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) climbed 14.2% to $36.66. Jefferies analyst Yaron Kinar upgraded Root from Hold to Buy and raised the price target from $10 to $40.</li>
<li>Crinetics Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crnx#NASDAQ">CRNX</a>) gained 12.1% to $45.91 following quarterly results.</li>
<li>MasTec, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtz#NYSE">MTZ</a>) gained 11.2% to $83.89 following strong quarterly results.</li>
<li>PTC Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptct#NASDAQ">PTCT</a>) rose 10.4% to $31.11 following quarterly results.</li>
<li>Rambus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmbs#NASDAQ">RMBS</a>) climbed 9.3% to $64.76. Rambus initiated accelerated share repurchase program to repurchase an aggregate of $50 million of its common stock.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) rose 9.3% to $35.10.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) gained 9.3% to $8.13.</li>
<li>Transocean Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rig#NYSE">RIG</a>) climbed 9.3% to $5.12.</li>
<li>Arvinas, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arvn#NASDAQ">ARVN</a>) gained 9.2% to $50.21. Barclays analyst Peter Lawson maintained Arvinas with an Overweight and raised the price target from $26 to $60.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldx#NASDAQ">CLDX</a>) climbed 8.7% to $52.27. Celldex Therapeutics priced upsized $400 million public offering of 8.52 million common stock at $47 per share.</li>
<li>Dyne Therapeutics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NYSE">DYN</a>) gained 7.9% to $29.03.</li>
<li>Celestica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cls#NYSE">CLS</a>) rose 7.7% to $45.81.</li>
<li>MoonLake Immunotherapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mltx#NASDAQ">MLTX</a>) gained 6.6% to $51.40. Needham analyst Serge Belanger reiterated MoonLake with a Buy and maintained a $66 price target.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) rose 6.3% to $921.40.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37422012/bitcoin-ethereum-move-lower-sats-mantle-among-top-losers"> Bitcoin, Ethereum Move Lower; SATS, Mantle Among Top Losers</a>

In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters&#39; option, if any, of approximately&nbsp;$400.4 million, excluding underwriting discounts and commissions and other offering-related expenses. The offering is expected to close on&nbsp;or about March 5, 2024, subject to customary closing conditions

Reported Earlier, Celldex Therapeutics Prices Upsized $400M Public Offering Of 8.52M Common Stock At $47/Share

All of the shares of common stock are being offered by the Company.

Offerings

Celldex Therapeutics Proposes To Offer And Sell $250M Of Shares Of Its Common Stock Via Public Offering

Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and raises the price target from $72 to $90.

Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $90

Shares of Freshpet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frpt#NASDAQ">FRPT</a>) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Freshpet posted quarterly earnings of 31 cents per share, beating market estimates of 5 cents per share. The company&rsquo;s quarterly sales came in at $215.42 million versus expectations of $204.36 million.
Freshpet shares gained 15.5% to $106.29 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) shares jumped 126% to $0.5009 after the company reported positive results from Shionogi&#39;s Phase 3 clinical trial of localized version of Akili&#39;s EndeavorRx&reg; for Pediatric ADHD patients in Japan.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) climbed 126% to $1.81 after surging over 30% on Friday.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) gained 107% to $13.71 after tumbling 40% on Friday.</li>
<li>Neptune Wellness Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) rose 54.6% to $0.49.</li>
<li>Interactive Strength Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trnr#NASDAQ">TRNR</a>) surged 32.2% to $0.8701 after the company announced it has entered into an exclusive worldwide distribution agreement with WOODWAY to sell and distribute CLMBR.</li>
<li>Agiliti, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agti#NASDAQ">AGTI</a>) gained 29.4% to $9.89 after the company announced it will be taken private by THL Partners.</li>
<li>Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) surged 28.8% to $143.34 after the company reported better-than-expected financial results.</li>
<li>R1 RCM Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcm#NYSE">RCM</a>) surged 26.7% to $14.06 after the company received an acquisition offer for the company valued at $13.75 per share.</li>
<li>Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) gained 26.3% to $1.2880.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) surged 22.1% to $11.24.</li>
<li>Milestone Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mist#NASDAQ">MIST</a>) gained 21.3% to $2.10 after the company announced plans to resubmit the New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT).</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) climbed 18.9% to $0.9451.</li>
<li>ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) gained 18% to $ 4.1250.</li>
<li>Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) rose 16.2% to $40.44 after the company reported fourth-quarter financial results above estimates and issued first-quarter guidance.</li>
<li>Nuwellis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuwe#NASDAQ">NUWE</a>) shares rose 16.1% to $0.7101.</li>
<li>SkyWater Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skyt#NASDAQ">SKYT</a>) gained 15.4% to $10.98.</li>
<li>ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) gained 14.3% to $3.9999 after dipping 33% on Friday.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldx#NASDAQ">CLDX</a>) surged 13.9% to $43.00 following strong quarterly sales.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) gained 13.4% to $1.4850.</li>
<li>Itron, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/itri#NASDAQ">ITRI</a>) rose 12.3% to $84.11 after the company reported fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>HashiCorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcp#NASDAQ">HCP</a>) gained 11.8% to $24.77 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $23 to $30.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) jumped 11.2% to $26.67.</li>
<li>NeuBase Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbse#NASDAQ">NBSE</a>) shares surged 10.5% to $0.83. Neubase Therapeutics, on Feb. 22, said board determined for company to dissolve, liquidate and distribute to stockholders its available assets.</li>
<li>Carmell Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctcx#NASDAQ">CTCX</a>) rose 9.9% to $2.47. Carmell announced product development has been completed for Gold Limited Edition Exclusive launch in March 2024.</li>
<li>Domino&#39;s Pizza, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dpz#NYSE">DPZ</a>) gained 8.2% to $469.01 after the company&rsquo;s fourth quarter 2023 earnings surpassed Wall Street expectations, raised its quarterly dividend, and announced an additional share buyback plan.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) rose 6.5% to $5.75. The company on Monday announced that it entered into a technology license agreement with Forseven Limited.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/teva#NYSE">TEVA</a>) shares gained 4.3% to $13.44 after the company announced FDA approval of its arthritis treatment.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aclarion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acon#NASDAQ">ACON</a>) shares fell 62.5% to $0.34 after the company priced its public offering of 5.175 million units. Each unit includes one share of common stock (or a pre-funded warrant), and two common warrants.</li>
<li>Venus Concept Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vero#NASDAQ">VERO</a>) dipped 28.8% to $0.93 after the company announced a $1.2 million registered direct offering at $1.465 per share.</li>
<li>DIH Holding US, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dhai#NASDAQ">DHAI</a>) fell 28.3% to $0.79.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thmo#NASDAQ">THMO</a>) dipped 27.5% to $0.7601.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) fell 25.1% to $7.18 after the company said its lunar lander may have tipped over upon landing on the moon.</li>
<li>Semilux International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/selx#NASDAQ">SELX</a>) declined 24.4% to $0.8615.</li>
<li>Brera Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brea#NASDAQ">BREA</a>) fell 21.8% to $0.8601.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aehl#NASDAQ">AEHL</a>) dipped 21.8% to $1.50. Antelope Enterprise announced closing of $1.3 million registered direct offering and private placement.</li>
<li>NGM Biopharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ngm#NASDAQ">NGM</a>) fell 19.4% to $1.5399. NGM Bio has entered into a definitive agreement and plan of merger with certain affiliates of the Column Group, LP.</li>
<li>Telesis Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbio#NASDAQ">TBIO</a>) shares fell 17.8% to $0.6401. Telesis Bio shares jumped 72% on Friday after the company was granted EUR Patent #3503915 for &quot;Genetically Engineered Vibrio Natriegens (Host Organism For Cloning And Manipulating DNA).&quot;</li>
<li>Beneficient (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/benf#NASDAQ">BENF</a>) fell 17% to $0.1640. On Feb. 13, Beneficient posted a third-quarter loss of $1.98 per share.</li>
<li>Dogness (International) Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dogz#NASDAQ">DOGZ</a>) fell 17% to $6.14.</li>
<li>AtlasClear Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atch#NYSE">ATCH</a>) shares fell 11.2% to $2.3450 after jumping over 131% on Friday.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) declined 11.2% to $6.30.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) fell 9.9% to $1.4599 after tumbling 11% on Friday.</li>
<li>Surgery Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgry#NASDAQ">SGRY</a>) dipped 7.8% to $30.43 following weak quarterly sales.</li>
<li>World Acceptance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wrld#NASDAQ">WRLD</a>) fell 7% to $120.71. World Acceptance recently reported better-than-expected third-quarter financial results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37283655/intuit-to-rally-around-14-here-are-10-top-analyst-forecasts-for-friday"> Intuit To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday </a>

Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session

WIIM

Celldex Therapeutics shares are trading higher after the company reported better-than-expected Q4 revenue results.

Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) reported its Q4 earnings results on Monday, February 26, 2024 at 07:01 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Celldex Therapeutics missed estimated earnings by -12.0%, reporting an EPS of $-0.83 versus an estimate of $-0.74.
Revenue was up $2.52 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.13 which was followed by a 8.0% increase in the share price the next day.
Here's a look at Celldex Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.68</td>
<td>-0.67</td>
<td>-0.63</td>
<td>-0.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.81</td>
<td>-0.65</td>
<td>-0.62</td>
<td>-0.56</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>580K</td>
<td>530K</td>
<td>410K</td>
<td>260K</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.52M</td>
<td>268K</td>
<td>967K</td>
<td>1.61M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Celldex Therapeutics <a href="https://www.benzinga.com/quote/CLDX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Celldex Therapeutics: Q4 Earnings Insights

Celldex Therapeutics Entered Deal To Sell Shares Of Up To $300M Common Stock Offering From Time To Time

Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.74) by 12.16 percent. This is a 48.21 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $4.13 million which beat the analyst consensus estimate of $840.00 thousand by 391.67 percent. This is a 156.04 percent increase over sales of $1.61 million the same period last year.

Celldex Therapeutics Q4 EPS $(0.83) Misses $(0.74) Estimate, Sales $4.13M Beat $840.00K Estimate

Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - 
- Sustained activity with rapid onset within 2 weeks - 
- Similar improvement in omalizumab-experienced/refractory and omalizumab-na&iuml;ve disease consistent with unique mechanism of action - 
- Favorable safety profile - 
- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 - 
- Company to host webcast February 25th at 9:45 am ET-

Celldex Therapeutics Earlier Announced Phase 2 Results For Barzolvolimab In Chronic  Spontaneous Urticaria Patients, Meeting Primary and Secondary Endpoints

Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) today announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2024 being held in Washington, DC on February 23-26, 2024. Abstracts will be available on the meeting website today, February 5, 2024.
Presentation details are below:
Abstract Title: Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial Presenting Author: Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin Session: Late Breaking Oral Abstract Session Date/Time: Saturday, February 24 at 2:05 pm - 2:15 pm ET
The abstract is comprised of the topline 12-week primary endpoint results the Company disclosed on November 6, 2023.
The Phase 2 randomized, double-blind, placebo-controlled, parallel group study is evaluating the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then enter a 36-week active treatment period, in which patients not already randomized to barzolvolimab at 150 mg every 4 weeks or 300 mg every 8 weeks are randomized 1:1 to receive one of these two dose regimens; patients already randomized to these treatment arms remain on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients then enter a follow-up period for an additional 24 weeks. The primary endpoint of the study is mean change in baseline to Week 12 in UAS7. Secondary endpoints include other assessments of safety and clinical activity including ISS7, HSS7 and AAS7.
Webcast and Conference Call The Company will host a webcast presentation of the data on Sunday, February 25th at 9:45 AM ET. The event will be webcast live and can be accessed by going to the "Events &amp; Presentations" page under the "Investors &amp; Media" section of the Celldex Therapeutics website at <a href="https://www.globenewswire.com/Tracker?data=1luU5F3QwUAXGcvKM-GvTqi7xUzKLdndTznk8jJtGAJwUV89bNcumY3NwJidjFfEnibQDjMZKmHWOYsV8kZTYw==">www.celldex.com</a>.

Events

Celldex Announces Upcoming Presentation Of Barzolvolimab Phase 2 Results In Chronic Spontaneous Urticaria At AAAAI 2024

In the last three months, 5 analysts have published ratings on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $53.4, a high estimate of $80.00, and a low estimate of $27.00. A 15.91% drop is evident in the current average compared to the previous average price target of $63.50. 
<img src="https://www.benzinga.com/files/images/story/2023/1703098838_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Celldex Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$54.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$54.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Celldex Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Celldex Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Celldex Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celldex Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
<h3>Celldex Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Celldex Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 272.73%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -2522.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Celldex Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.6%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.2%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Celldex Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics

TD Cowen analyst Yaron Werber initiates coverage on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Outperform rating.

Initiation

TD Cowen Initiates Coverage On Celldex Therapeutics with Outperform Rating

Celldex prices $400.4M stock offering

The 65 rating InvestorsObserver gives to Celldex Therapeutics, Inc. (CLDX)  stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 74 percent of stocks in the Biotechnology industry, CLDX's 65 overall rating means the stock scores better than 65 percent of all stocks. CLDX has an Overa

Celldex Therapeutics, Inc. (CLDX) has gained 36.87% in a Week, Should You Sell?

Celldex Therapeutics, Inc. (CLDX) is near the top in its sector according to InvestorsObserver.CLDX gets an overall rating of 84. That means it scores higher than 84% of stocks.Celldex Therapeutics, Inc. gets a 87 rank in the Healthcare sector. Healthcare is number 1 out of 11 sectors. CLDX has an Overall Score of 84. Find

Should You Add Celldex Therapeutics, Inc. (CLDX) Stock to Your Portfolio Friday?

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Celldex (CLDX – Research Report). The associated price target remai...

Celldex's Barzolvolimab Shows Promise for Urticaria Treatment: A Strong Buy Recommendation

Celldex GAAP EPS of -$0.56, revenue of $0.16M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Celldex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cldx-stock-quote/">CLDX</a>) just reported results for the first quarter of 2024.<ul><li>Celldex Therapeutics reported earnings per share of -56 cents. This was above the analyst estimate for EPS of -69 cents.</li><li>The company reported revenue of $156,000.</li><li>This was 83.04% worse than the analyst estimate for revenue of $920,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cldx-stock-earnings-celldex-therapeutics-for-q1-of-2024/">CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024

Celldex Buy Rating Affirmed by Analyst Joseph Pantginis on Strong Q1 Performance and Promising Drug Pipeline

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Celldex (CLDX – Research Report). The associated price target was lowere...

Buy Rating Affirmed for Celldex on Strong Barzolvolimab Trial Results and Positive Outlook

Celldex (CLDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 6. Analyst Thomas Smith from Leerink...

Celldex Therapeutics: A Strong Buy on Impressive Barzolvolimab Results and Promising Pipeline

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Celldex (CLDX – Research Report), Siemens Healthineers AG (SEMHF ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Siemens Healthineers AG (OtherSEMHF) and uniQure (QURE)

QURE

SEMHF

Health Care

Press Releases

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

IPOs

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Celldex Therapeutics Stock (NASDAQ:CLDX), Short Interest Report

People Also Watch